Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.278,91
0,60%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Adverum Biotechnologies Inc (ADVM) Adverum Biotechnologies Inc (ADVM) Notizie

Adverum Biotechnologies Inc

ADVM
10,43
0,43 (4,30%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/5/202414:00GLOBEAdverum Biotechnologies to Participate in Upcoming May..
25/4/202422:05GLOBEAdverum Biotechnologies to Present LUNA 26-week Phase 2..
18/3/202421:05GLOBEAdverum Biotechnologies Reports Fourth Quarter and Full Year..
04/3/202422:40EDGAR2Form S-3 - Registration statement under Securities Act of..
28/2/202422:05GLOBEAdverum Biotechnologies to Participate in the TD Cowen 44th..
22/2/202421:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202421:39EDGAR2Form D - Notice of Exempt Offering of Securities
15/2/202422:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
15/2/202402:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202414:00GLOBEAdverum Biotechnologies to Participate in the Oppenheimer..
09/2/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202417:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202414:45EDGAR2Form 8-K - Current report
08/2/202413:00GLOBEAdverum Biotechnologies Announces Positive Preliminary..
06/2/202422:47EDGAR2Form 8-K - Current report
05/2/202423:03EDGAR2Form 8-K - Current report
05/2/202413:45GLOBEAdverum Biotechnologies Announces $127.5 Million Private..
01/2/202423:30GLOBEAdverum Biotechnologies will Host Webcast to Review LUNA..
29/1/202414:00GLOBEAdverum Biotechnologies Appoints Romuald Corbau, Ph.D. as..
08/12/202322:11EDGAR2Form 8-K - Current report
07/12/202322:05GLOBEAdverum Biotechnologies to Present LUNA Preliminary Efficacy..
04/12/202322:09EDGAR2Form 8-K/A - Current report: [Amend]
28/11/202322:05GLOBEAdverum Biotechnologies to Participate in the Evercore ISI..
09/11/202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:07EDGAR2Form 8-K - Current report
09/11/202322:05GLOBEAdverum Biotechnologies Reports Third Quarter 2023 Financial..
07/11/202301:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202301:52EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/11/202322:10EDGAR2Form 8-K - Current report
06/11/202314:00GLOBEAdverum Biotechnologies Appoints C. David Nicholson, Ph.D...
04/11/202322:54GLOBEAdverum Biotechnologies Announces 3-Year Efficacy and Safety..
26/9/202322:05GLOBEAdverum Biotechnologies Announces Positive Aflibercept..
21/9/202322:05GLOBEAdverum Biotechnologies to Participate in Upcoming Investor..
19/9/202300:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:05GLOBEAdverum Biotechnologies to Participate in the H.C...
21/8/202322:05GLOBEAdverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as..
14/8/202314:00GLOBEAdverum Biotechnologies to Participate in the H.C...
10/8/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:09EDGAR2Form 8-K - Current report
10/8/202322:05GLOBEAdverum Biotechnologies Completes Enrollment of Phase 2 LUNA..
04/8/202322:18EDGAR2Form 8-K - Current report
24/7/202322:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/6/202314:00GLOBEAdverum Biotechnologies Grants License to Ray Therapeutics..
02/6/202314:00GLOBEAdverum Biotechnologies to Participate in the Jefferies..
25/5/202312:30GLOBEAdverum Biotechnologies Announces New Executive Leadership..
18/5/202315:00GLOBEAdverum Biotechnologies Introduces an Intravitreal Gene..
Apertura: 10,10 Min: 10,00 Max: 10,69
Chiusura: 10,00

La tua Cronologia

NASDAQ
ADVM
Adverum Biotechnologies
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network